244 related articles for article (PubMed ID: 36774933)
21. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Hellmann MD; Rizvi NA; Goldman JW; Gettinger SN; Borghaei H; Brahmer JR; Ready NE; Gerber DE; Chow LQ; Juergens RA; Shepherd FA; Laurie SA; Geese WJ; Agrawal S; Young TC; Li X; Antonia SJ
Lancet Oncol; 2017 Jan; 18(1):31-41. PubMed ID: 27932067
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J; Mandala M; Del Vecchio M; Gogas HJ; Arance AM; Cowey CL; Dalle S; Schenker M; Chiarion-Sileni V; Marquez-Rodas I; Grob JJ; Butler MO; Middleton MR; Maio M; Atkinson V; Queirolo P; Gonzalez R; Kudchadkar RR; Smylie M; Meyer N; Mortier L; Atkins MB; Long GV; Bhatia S; Lebbé C; Rutkowski P; Yokota K; Yamazaki N; Kim TM; de Pril V; Sabater J; Qureshi A; Larkin J; Ascierto PA;
N Engl J Med; 2017 Nov; 377(19):1824-1835. PubMed ID: 28891423
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ; Rutkowski P; Queirolo P; Del Vecchio M; Mackiewicz J; Chiarion-Sileni V; de la Cruz Merino L; Khattak MA; Schadendorf D; Long GV; Ascierto PA; Mandala M; De Galitiis F; Haydon A; Dummer R; Grob JJ; Robert C; Carlino MS; Mohr P; Poklepovic A; Sondak VK; Scolyer RA; Kirkwood JM; Chen K; Diede SJ; Ahsan S; Ibrahim N; Eggermont AMM;
Lancet; 2022 Apr; 399(10336):1718-1729. PubMed ID: 35367007
[TBL] [Abstract][Full Text] [Related]
26. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
[TBL] [Abstract][Full Text] [Related]
27. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
[TBL] [Abstract][Full Text] [Related]
28. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P; Scherpereel A; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Jahan T; Antonia S; Oulkhouir Y; Bautista Y; Cornelissen R; Greillier L; Grossi F; Kowalski D; Rodríguez-Cid J; Aanur P; Oukessou A; Baudelet C; Zalcman G
Lancet; 2021 Jan; 397(10272):375-386. PubMed ID: 33485464
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV; Luke JJ; Khattak MA; de la Cruz Merino L; Del Vecchio M; Rutkowski P; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Kirkwood JM; Robert C; Grob JJ; de Galitiis F; Schadendorf D; Carlino MS; Mohr P; Dummer R; Gershenwald JE; Yoon CH; Wu XL; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Ascierto PA;
Lancet Oncol; 2022 Nov; 23(11):1378-1388. PubMed ID: 36265502
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
[TBL] [Abstract][Full Text] [Related]
31. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C; Wang Z; Sun Y; Cao L; Ma Z; Wu R; Yu Y; Yao W; Chang J; Chen J; Zhuang W; Cui J; Chen X; Lu Y; Shen H; Wang J; Li P; Qin M; Lu D; Yang J
Lancet Oncol; 2022 Feb; 23(2):220-233. PubMed ID: 35038432
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Pal SK; Uzzo R; Karam JA; Master VA; Donskov F; Suarez C; Albiges L; Rini B; Tomita Y; Kann AG; Procopio G; Massari F; Zibelman M; Antonyan I; Huseni M; Basu D; Ci B; Leung W; Khan O; Dubey S; Bex A
Lancet; 2022 Oct; 400(10358):1103-1116. PubMed ID: 36099926
[TBL] [Abstract][Full Text] [Related]
33. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
37. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Reiss KA; Mick R; Teitelbaum U; O'Hara M; Schneider C; Massa R; Karasic T; Tondon R; Onyiah C; Gosselin MK; Donze A; Domchek SM; Vonderheide RH
Lancet Oncol; 2022 Aug; 23(8):1009-1020. PubMed ID: 35810751
[TBL] [Abstract][Full Text] [Related]
38. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
40. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
